medigraphic.com
SPANISH

Revista Mexicana de Patología Clínica y Medicina de Laboratorio

ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2007, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2007; 54 (1)

Hepatic Phaseolus:
Biological cycle and biotic potential

Carrada-Bravo T
Full text How to cite this article

Language: Spanish
References: 10
Page: 21-27
PDF size: 190.16 Kb.


Key words:

Fasciola hepatica, life cycle, biotic potential.

ABSTRACT

The definite hosts of Fasciola hepatica are sheeps, cows, and humans. The intermediate host is a hermaphroditic lymnaeid snail Major sources of human´s infections are fresh watercress, alfalfa, lettuce or drinking water. When encysted metacercaria are swallowed by a human, they excyst in the lumen of the intestine and migrate toward the liver, where it feeds upon hepatocytes, causing necrosis and haemorrhages. F. hepatica grows slowly achieving maturity after two months into the bile–ducts, the parasite is hermaphroditic, and self–mating occurs. Eggs are laid unembrionated and are passed from bile–ducts to duodenum, to be excreted by faeces. The egg must be deposited in fresh, slow–moving water to complete development. After hatching, the ciliated miracidium swims and seeks a snail and multiplies asexually within its tissue. Larval morphogenesis proceeds sequentially from mature sporocyst to the first and second redia–stage. Each redia gives rise to many cercaria which may encyst upon aquatic plants producing metacercaria, mildly resistant to environmental changes. Livestock infections induces productivity losses of meat and milk, of adverse economic consequences. Human fasciolosis is an important reemerging disease: 17 million humans are probably infected, but in Latinoamerican countries the known incidence of human infection has increased significantly. Prevalence–rates between 72 and 100% have been recorded in the Bolivian Highlands.


REFERENCES

  1. Carrada–Bravo T. Fascioliasis. Diagnóstico, epidemiología y tratamientos. Rev Gastroenterol Mex 2003; 8: 135–142.

  2. De Haro–Arteaga I. Fasciolosis. En: Becerril–Flores MA, Romero–Cabello R. Parasitología médica de las moléculas a la enfermedad. México: Mc Graw–Hill–Interamer 2004: 157–163.

  3. Gutiérrez-Galindo JF. Fasciolosis bovina http: www. Exopol.com/defaulf.html versión1/2005.

  4. Bennett R, Christiansen K, Hadley R. Preliminary estimates of the direct cost associated with endemic diseases of livestock in Great Britain. Prevent Vet Med 1999; 39: 155-171.

  5. Carrada–Bravo T, Escamilla–Martínez JR. Fasciolosis revisión clínico–epidemiológica actualizada. Rev Mex Patol Clin 2005; 52: 83–96.

  6. Hurtrez–Obuses S, Meunier C, Dusand P, Renaud F. Dynamic of host-parasite infections: The example of population biology of the liver fluke (Fasciola hepatica). Microbes Infect 2001; 3: 841-849.

  7. Teegen WR D. The presence of Fasciola hepatica (liver–fluke) in humans and catle from a 4,500 year archeological site in the Saale–Unstrut Valley, Germany. Mem Inst Oswaldo Cruz 2003; 98 Suppl 141– 3: 1–6.

  8. González–Lanza C, Manga Y, del Pozo P, Hidalgo R. Dynamics of elimination of eggs of Fasciola hepatica (Trematoda, Digenea) in the faeces of cattle in the Porna basin, Spain. Veter Parasitol 1989; 34: 35–43.

  9. Marcos–Raymundo LA, Maco–Flores V, Terashima A, Samalvides F, Miranda E, Tantalean M y cols. Hiperendemicidad de Fasciolosis humana en el Valle de Mantaro, Perú: Factores de riesgo de la infección por Fasciola hepatica. Rev Gastroenterol Perú 2004; 24: 6–20.

  10. Esteban JG, Flores A, Angeles R, Mas Comas MS. High endemicity of human fasciolosis between lake Titicaca and La Paz Valley, Bolivia. Trans Roy Soc Trop Med Hyg 1999; 93: 151–156.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Mex Patol Clin Med Lab. 2007;54